BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound
BioHarvest Sciences Inc. (NASDAQ: BHST) has secured a new CDMO (Contract Development and Manufacturing Organization) contract to develop a plant-based fragrance compound from a threatened plant species. The company will utilize its Botanical Synthesis technology platform and AI-assisted research capabilities for this project targeting the multi-billion-dollar fragrance market.
The Stage 1 contract focuses on developing cell banks for future production of targeted fragrance molecules, with milestone-based payments. Upon successful completion, Stage 2 would involve compound production in liquid media. This agreement expands BioHarvest's CDMO portfolio beyond pharmaceuticals and nutrition into the fragrance industry while contributing to rare plant species conservation.
BioHarvest Sciences Inc. (NASDAQ: BHST) ha ottenuto un nuovo contratto CDMO (Contract Development and Manufacturing Organization) per sviluppare un composto profumato a base vegetale derivato da una specie vegetale minacciata. L'azienda utilizzerà la sua piattaforma tecnologica Botanical Synthesis e le capacità di ricerca assistita dall'IA per questo progetto rivolto al mercato delle fragranze, che vale miliardi di dollari.
Il contratto di Fase 1 si concentra sulla creazione di banche cellulari per la futura produzione delle molecole profumate mirate, con pagamenti basati su obiettivi raggiunti. Al completamento con successo, la Fase 2 prevedrà la produzione del composto in un mezzo liquido. Questo accordo amplia il portafoglio CDMO di BioHarvest oltre i settori farmaceutico e nutrizionale, includendo l'industria delle fragranze e contribuendo alla conservazione delle specie vegetali rare.
BioHarvest Sciences Inc. (NASDAQ: BHST) ha asegurado un nuevo contrato CDMO (Organización de Desarrollo y Fabricación por Contrato) para desarrollar un compuesto de fragancia a base de plantas proveniente de una especie vegetal amenazada. La empresa utilizará su plataforma tecnológica Botanical Synthesis y capacidades de investigación asistidas por IA para este proyecto dirigido al mercado multimillonario de fragancias.
El contrato de la Fase 1 se centra en desarrollar bancos celulares para la futura producción de las moléculas de fragancia objetivo, con pagos basados en hitos. Tras la finalización exitosa, la Fase 2 implicaría la producción del compuesto en medios líquidos. Este acuerdo amplía el portafolio CDMO de BioHarvest más allá de la farmacéutica y la nutrición hacia la industria de fragancias, contribuyendo además a la conservación de especies vegetales raras.
BioHarvest Sciences Inc. (NASDAQ: BHST)는 멸종 위기에 처한 식물 종에서 유래한 식물 기반 향료 화합물을 개발하기 위한 새로운 CDMO(계약 개발 및 제조 조직) 계약을 체결했습니다. 회사는 이 프로젝트를 위해 Botanical Synthesis 기술 플랫폼과 AI 지원 연구 역량을 활용할 예정이며, 이 프로젝트는 수십억 달러 규모의 향료 시장을 목표로 합니다.
1단계 계약은 향료 분자 생산을 위한 세포 은행 개발에 중점을 두며, 마일스톤 기반 지급이 이루어집니다. 성공적으로 완료되면 2단계에서는 액체 배지에서 화합물 생산이 진행됩니다. 이번 계약은 BioHarvest의 CDMO 포트폴리오를 제약 및 영양 분야를 넘어 향료 산업으로 확장하는 동시에 희귀 식물 종 보존에도 기여합니다.
BioHarvest Sciences Inc. (NASDAQ : BHST) a obtenu un nouveau contrat CDMO (Contract Development and Manufacturing Organization) pour développer un composé parfumé à base de plantes provenant d'une espèce végétale menacée. L'entreprise utilisera sa plateforme technologique Botanical Synthesis ainsi que ses capacités de recherche assistée par IA pour ce projet ciblant le marché des parfums, qui pèse plusieurs milliards de dollars.
Le contrat de la Phase 1 porte sur le développement de banques cellulaires pour la production future des molécules parfumées ciblées, avec des paiements basés sur des jalons. En cas de réussite, la Phase 2 consistera à produire le composé en milieu liquide. Cet accord élargit le portefeuille CDMO de BioHarvest au-delà des secteurs pharmaceutique et nutritionnel pour inclure l'industrie du parfum, tout en contribuant à la conservation des espèces végétales rares.
BioHarvest Sciences Inc. (NASDAQ: BHST) hat einen neuen CDMO-Vertrag (Contract Development and Manufacturing Organization) abgeschlossen, um eine pflanzenbasierte Duftstoffverbindung aus einer bedrohten Pflanzenart zu entwickeln. Das Unternehmen wird seine Botanical Synthesis-Technologieplattform und KI-gestützte Forschungskapazitäten für dieses Projekt nutzen, das auf den milliardenschweren Duftstoffmarkt abzielt.
Der Vertrag der Phase 1 konzentriert sich auf die Entwicklung von Zellbanken für die zukünftige Produktion der Ziel-Duftmoleküle, mit zahlungen basierend auf Meilensteinen. Nach erfolgreichem Abschluss würde Phase 2 die Produktion der Verbindung in flüssigen Medien umfassen. Diese Vereinbarung erweitert das CDMO-Portfolio von BioHarvest über Pharmazeutika und Ernährung hinaus in die Duftstoffindustrie und trägt gleichzeitig zum Schutz seltener Pflanzenarten bei.
- Expansion into new high-value fragrance and scents market vertical
- Milestone-based payment structure provides additional revenue potential
- AI-driven capabilities enhance discovery process efficiency
- Growing CDMO portfolio demonstrates platform versatility
- Stage 1 contract with uncertain progression to Stage 2
- Non-disclosure agreement limits transparency on specific terms and potential value
Insights
BioHarvest expands business with new fragrance CDMO contract, utilizing AI to develop sustainable alternatives for threatened plant compounds.
BioHarvest's announcement represents a strategic expansion of their Botanical Synthesis platform into the multi-billion-dollar fragrance market, diversifying beyond their existing pharmaceutical and nutrition CDMO projects. The company has secured a Stage 1 contract to develop plant-based fragrance compounds from threatened plant species, with milestone-based payments structured into the agreement.
What makes this development noteworthy is BioHarvest's application of AI-assisted research capabilities to identify optimal plant cells for development into cell banks capable of producing targeted fragrance molecules. This demonstrates the company's technological evolution and ability to leverage advanced tools to enhance their proprietary platform.
The two-stage approach is typical for CDMO contracts: Stage 1 focuses on developing cell cultures in petri dishes, while Stage 2 would involve production in liquid media—a prerequisite for potential volume manufacturing. This methodical path to commercialization reduces upfront investment while preserving upside potential through milestone payments.
From a sustainability perspective, BioHarvest is positioning its technology as a solution for preserving threatened plant species that face overharvesting and habitat loss. This aligns with growing consumer and industry demand for environmentally responsible sourcing practices in the fragrance sector.
While financial details remain undisclosed due to confidentiality agreements, this expansion into fragrances demonstrates BioHarvest's platform versatility and potentially opens new revenue streams. The company appears to be executing on a diversification strategy that leverages their core technology across multiple high-value markets, which could strengthen their competitive positioning if successful in navigating the Stage 1 to Stage 2 transition.
First CDMO Project to Utilize In-house AI Tools for Discovery of Plant Cell Targets for the Botanical Synthesis Process
Rehovot, Israel--(Newsfile Corp. - May 21, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's Botanical Synthesis CDMO Services division has secured a new contract to develop a plant-based fragrance compound derived from a plant that is under significant threat due to over harvesting and habitat loss. This agreement is with a new commercial partner targeting the multi-billion-dollar fragrance and scents market.
Ahead of the signing of this Stage 1 contract, BioHarvest leveraged its advanced AI-assisted research capabilities to identify the specific plant species most likely to develop into the required cell bank for future efficient production of the targeted fragrance and scent molecules. Stage 1 of the contract utilizes the Company's proprietary Botanical Synthesis platform to mirror, magnify and multiply the plant's targeted cells in petri dishes. A successful outcome of Stage 1 would be a customer decision to advance the compound to Stage 2, which involves production of the compound in liquid media, a necessary step towards potential future volume manufacturing.
The agreement is structured with milestone-based payments and includes a non-disclosure agreement covering Stage 1. This new contract builds on BioHarvest's growing CDMO portfolio and demonstrates the versatility of its platform to address new verticals, including the multi-billion-dollar fragrance and scents market.
Ilan Sobel, CEO of BioHarvest, commented: "This agreement expands the reach of our Botanical Synthesis platform into the high-value fragrance space, adding to our growing pipeline of pharmaceutical and nutrition-focused CDMO projects. Fragrance compounds like these drive billions in global sales, and this contract is further validation of BioHarvest's ability to deliver scalable, high-impact solutions across industries whilst playing an important role in conserving threatened rare plant species and protecting the planet for generations to come. Combined with the strong commercial performance of our nutraceutical division, it is clear that our Botanical Synthesis platform has matured into a transformative technology reshaping access to the world's most valuable plant-based compounds."
Dr. Zaki Rakib, Chairman and President of the CDMO Services Division, concluded: "The successful commercialization of these fragrance compounds could represent a breakthrough in how highly sought-after botanical products are produced. Every CDMO engagement strengthens our AI-driven discovery capabilities, and we are excited to launch this Stage 1 partnership with such a respected partner. This marks an exciting first step for BioHarvest into the global fragrance and scents market."
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. There is no assurance that signed research agreements will proceed past a contracted stage, or that a developed molecule or compound will be commercialized. Successful commercialization of any compound developed will be subject to consumer preferences, advertising budgets and other factors affecting market acceptance of new products which are uncertain and cannot be assured. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
+1 (604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHST@mzgroup.us
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252897
FAQ
What is the purpose of BioHarvest's (BHST) new CDMO contract?
How is BHST's new fragrance development contract structured?
What markets will BioHarvest's (BHST) new fragrance contract target?
How does BioHarvest's technology help protect threatened plant species?
What role does AI play in BioHarvest's (BHST) new fragrance development project?
